A5007476960- Systemic Lupus Erythematosus Research
- Chronic Kidney Disease and Diabetes
- Atherosclerosis and Cardiovascular Diseases
- Pharmacological Effects of Natural Compounds
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Dialysis and Renal Disease Management
- Diabetes Treatment and Management
- Lymphoma Diagnosis and Treatment
- Erythrocyte Function and Pathophysiology
- Diabetes Management and Research
- Renal Diseases and Glomerulopathies
- Blood properties and coagulation
- Diabetes and associated disorders
- Liver Diseases and Immunity
Seoul National University
2024-2025
Hanyang University Seoul Hospital
2022-2024
Background Although treatment guidelines exist, referrals and discussions among clinicians about the disease can lead to more appropriate for patient. This study evaluated effects of from diabetes clinics nephrologists on kidney function in type 2 diabetic patients through causal inference analysis. Methods Patients with mellitus (DM) who initially visited clinic were either referred (referral group) or continued under care diabetologists at (non-referral group). The slope estimated...
BackgroundDue to the limited availability of therapeutic agents for type 2 diabetic kidney disease (T2DKD), there is a need further knowledge derived from experimental models and innovative techniques. In addressing this issue, single-cell RNA sequencing (scRNA-seq) has been exclusively applied genetically modified model, but not an induced model representing T2DKD. Herein, we analyzed scRNA-seq other experiments T2DKD validated results in human-derived biospecimens. MethodsThe was by...
<h3>Background:</h3> The lupus low disease activity state (LLDAS) is a treat-to-target that has been prospectively validated as protective from organ damage, death, and loss of health-related quality life for patients with SLE. 2023 EULAR recommendations the management SLE advised glucocorticoid (GC) dose no more than 5mg/day [1] whereas GC threshold in definition LLDAS 7.5mg/day [2]. <h3>Objectives:</h3> We sought to determine if lowering ceiling 5 mg/day (LLDAS-5) was associated improved...
<h3>Background:</h3> In patients with systemic lupus erythematosus (SLE), treatment options are limited. Anti-malarials and immunosuppressive therapies widely used even though toxicity intolerance may limit persistence, or 'survival'. The predictors impact of drug survival anti-malarials in SLE unknown. <h3>Objectives:</h3> We sought to identify patient disease-related factors that associated anti-malarial (AM) immunosuppressant agents (IS) stable SLE. also analysed the on disease flares....
<h3>Background:</h3> While glucocorticoids and immunosuppressive therapies are key treatment approaches in SLE, these may contribute to damage accrual. Given the long horizon of tapering therapy stable SLE is often considered, but whether this approach impacts accrual unknown. <h3>Objectives:</h3> We aim compare time new among patients whose and/or were tapered after achieving target, versus those was continued on same doses. <h3>Methods:</h3> followed (ACR/SLICC criteria) from 13...
<h3>Background:</h3> There has been a long-standing interest in the use of biomarkers SLE, both to measure current disease activity and predict outcomes. Erythrocyte sedimentation rate (ESR), non-specific biomarker inflammation, shown correlate with SLE as well flares organ damage some studies, yet it is not used clinical trial endpoints. <h3>Objectives:</h3> We sought evaluate associations ESR flares, mortality large, multi-national cohort patients. <h3>Methods:</h3> Data were prospectively...
Mechanisms of progression diabetic kidney disease (DKD) are not completely understood. This study uses untargeted and targeted mass spectrometry-based proteomics in two independent cohorts on continents to decipher the mechanisms DKD patients with type 2 diabetes.
<h3>Background</h3> In SLE patients, episodes of high disease activity state (HDAS, SLEDAI-2K≥10) are associated with worse outcomes even if only experienced once. We investigated whether attainment the lupus low (LLDAS) was protection against adverse in patients after an episode HDAS. <h3>Objectives</h3> To compare LLDAS between HDAS and non-HDAS patients. <h3>Methods</h3> Data on 4,106 from a multinational cohort, collected prospectively 2013 2020, were analysed. Disease assessed using...
Background Lupus low disease activity state (LLDAS) attainment has been reported to be associated with reduced damage accrual, flare, and mortality, as well improved quality of life, in cohorts SLE patients established disease. Whether these associations are present recent-onset is less known. Objectives To evaluate the LLDAS outcomes recent onset SLE. Methods Data from a 13-country longitudinal cohort (ACR/SLICC criteria) were collected prospectively between 2013 2020 using standard...
<h3>Background</h3> Some studies demonstrated that withdrawal of low-dose glucocorticoids in clinically quiescent systemic lupus erythematosus (SLE) patients increased the risk flare [1]. An international survey 130 clinicians showed persistent abnormal serology led to a reluctance reduce or discontinue medications [2]. <h3>Objectives</h3> To assess and damage accrual after tapering serologically active (SACQ) with SLE. Association other SACQ was also analyzed. <h3>Methods</h3> We used data...
<h3>Background</h3> The lupus low disease activity state (LLDAS) treat-to-target definition sets a ceiling for acceptable and treatment burden in SLE. Definition of Remission SLE (DORIS) is more stringent state, but as it concentric with LLDAS many patients also meet the DORIS remission definition. Studies cohorts majority poorly separate remission, leading to debate about independent effects on outcomes. <h3>Objectives</h3> We examined whether being not provided protection against adverse...